Figure 5

From: CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells

Figure 5

Expression of CD95 and CD95L is increasing in recurrent GBM. (a) Anti-CD95 and -CD95L immunohistochemistry (IHC) of primary and matching relapsing tumors (representative images, scale bar: 200 μm). (b) Scoring results for anti-CD95 IHC of 27 primary and relapsing tumors. (Wilcoxon test). (c) Individual relative CD95 scores (relapse score – primary tumor score) for the 27 patients showing an overall increase of CD95 expression in the relapsing tumors (average relative score=0.70, 95% Cl: 0.14–1.27). (d) Scoring results for anti-CD95L IHC of 27 primary and relapsing tumors. (Wilcoxon test). (e) Individual relative CD95L scores for 27 patients showing an overall increase in CD95L expression in the relapsing tumors (average relative score=0.73, 95% CI: 0.13–1.33)